LXREPAIR secures €1.1 million from seed funds for the development of its diagnostic kits in radiotherapy and chemotherapy
LXREPAIR, a French company specialized in the development of disruptive technologies for DNA repair characterization, announces it has raised €1.1M from KREAXI, CEA-Investment, XPAND INVESTMENT Ltd of the KIS Group, Grenoble Angels, Savoie Mont-Blanc Angels, Gentiane Participation and individual investors.
The funds will be used to complete LXRepair clinical proof of concepts in oncology, to obtain the CE marking of the kits and for international business development.